These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 9819842)

  • 1. Assessing uncertainty in microsimulation modelling with application to cancer screening interventions.
    Cronin KA; Legler JM; Etzioni RD
    Stat Med; 1998 Nov; 17(21):2509-23. PubMed ID: 9819842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Divergent Responses to Mammography and Prostate-Specific Antigen Recommendations.
    Martinez KA; Rothberg MB
    Am J Prev Med; 2017 Oct; 53(4):533-536. PubMed ID: 28318901
    [No Abstract]   [Full Text] [Related]  

  • 3. The use of modeling to understand the impact of screening on U.S. mortality: examples from mammography and PSA testing.
    Feuer EJ; Etzioni R; Cronin KA; Mariotto A
    Stat Methods Med Res; 2004 Dec; 13(6):421-42. PubMed ID: 15587432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating Parameter Uncertainty in a Simulation Model of Cancer Using Emulators.
    de Carvalho TM; Heijnsdijk EAM; Coffeng L; de Koning HJ
    Med Decis Making; 2019 May; 39(4):405-413. PubMed ID: 31179833
    [No Abstract]   [Full Text] [Related]  

  • 5. Combined application of information theory on laboratory results with classification and regression tree analysis: analysis of unnecessary biopsy for prostate cancer.
    Hwang SH; Pyo T; Oh HB; Park HJ; Lee KJ
    Clin Chim Acta; 2013 Jan; 415():133-7. PubMed ID: 23078854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate-specific antigen density and age-specific prostate-specific antigen values: the solution of prostate cancer screening?
    Paul R; Breul J; Hartung R
    Eur Urol; 1995; 27(4):286-91. PubMed ID: 7544733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends.
    Etzioni R; Penson DF; Legler JM; di Tommaso D; Boer R; Gann PH; Feuer EJ
    J Natl Cancer Inst; 2002 Jul; 94(13):981-90. PubMed ID: 12096083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Timely screening routines for prostatic cancer by Norwegian physicians].
    Fosså SD; Eri LM
    Tidsskr Nor Laegeforen; 1999 Oct; 119(24):3572-6. PubMed ID: 10563174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving doctor-patient understanding of probability in communicating cancer-screening test findings.
    Hanoch Y
    J Health Commun; 2004; 9(4):327-35. PubMed ID: 15371085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening for prostate cancer: updated experience from the Tyrol study.
    Horninger W; Berger A; Pelzer A; Klocker H; Oberaigner W; Schönitzer D; Severi G; Robertson C; Boyle P; Bartsch G
    Can J Urol; 2005 Feb; 12 Suppl 1():7-13; discussion 92-3. PubMed ID: 15780158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies.
    Roth JA; Gulati R; Gore JL; Cooperberg MR; Etzioni R
    JAMA Oncol; 2016 Jul; 2(7):890-8. PubMed ID: 27010943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Solving the overdiagnosis dilemma.
    Esserman L; Thompson I
    J Natl Cancer Inst; 2010 May; 102(9):582-3. PubMed ID: 20413743
    [No Abstract]   [Full Text] [Related]  

  • 13. Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.
    Bustad A; Terziivanov D; Leary R; Port R; Schumitzky A; Jelliffe R
    Clin Pharmacokinet; 2006; 45(4):365-83. PubMed ID: 16584284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effective prostate cancer detection. Reduction of low-yield biopsies. Investigators of the American Cancer Society National Prostate Cancer Detection Project.
    Littrup PJ; Kane RA; Mettlin CJ; Murphy GP; Lee F; Toi A; Badalament R; Babaian R
    Cancer; 1994 Dec; 74(12):3146-58. PubMed ID: 7526969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection.
    Ross KS; Carter HB; Pearson JD; Guess HA
    JAMA; 2000 Sep; 284(11):1399-405. PubMed ID: 10989402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening for prostate cancer using prostate-specific antigen alone as a first-line checkup parameter: results of the health checkup system.
    Uchida K; Takeshima H; Akaza H; Ono Y
    Jpn J Clin Oncol; 2000 Feb; 30(2):95-100. PubMed ID: 10768873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Part 2. Development of Enhanced Statistical Methods for Assessing Health Effects Associated with an Unknown Number of Major Sources of Multiple Air Pollutants.
    Park ES; Symanski E; Han D; Spiegelman C
    Res Rep Health Eff Inst; 2015 Jun; (183 Pt 1-2):51-113. PubMed ID: 26333239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Cost-Utility Analysis of Prostate Cancer Screening in Australia.
    Keller A; Gericke C; Whitty JA; Yaxley J; Kua B; Coughlin G; Gianduzzo T
    Appl Health Econ Health Policy; 2017 Feb; 15(1):95-111. PubMed ID: 27757918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
    Pinsky PF; Blacka A; Kramer BS; Miller A; Prorok PC; Berg C
    Clin Trials; 2010 Aug; 7(4):303-11. PubMed ID: 20571134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimation of prostate cancer risk on the basis of total and free prostate-specific antigen, prostate volume and digital rectal examination.
    Finne P; Auvinen A; Aro J; Juusela H; Määttänen L; Rannikko S; Hakama M; Tammela TL; Stenman UH
    Eur Urol; 2002 Jun; 41(6):619-26; discussion 626-7. PubMed ID: 12074779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.